Stock events for Protara Therapeutics, Inc. (TARA)
In September 2025, Protara Therapeutics was added to the S&P Global BMI Index. In November 2025, the company provided a STARBORN-1 Clinical Trial Interim Update. In December 2025, an interim data update for the SUO ADVANCED-2 Phase 2 BCG-Naive trial was announced with positive results. In January 2026, TARA-002 received FDA Breakthrough Therapy and Fast Track designations and was selected for the FDA's CDRP Program. Also in January 2026, the first patient was dosed in the THRIVE-3 trial for IV Choline Chloride, and Piper Sandler initiated coverage with an "Overweight" rating. In January 2026, the company highlighted updates and milestones, including a public offering to extend its cash runway into 2028. In February 2026, HC Wainwright reaffirmed a "buy" rating. In late February 2026, Protara's stock experienced a significant drop following the release of updated interim results from its Phase 2 ADVANCED-2 clinical trial. Protara Therapeutics held an ASCO-GU Update in February 2026 and participated in the Oppenheimer 36th Annual Healthcare Life Sciences Conference. In March 2026, JP Morgan initiated coverage with an "Overweight" rating.
Demand Seasonality affecting Protara Therapeutics, Inc.’s stock price
There is no indication of demand seasonality for Protara Therapeutics' products and services, as the medical conditions they address are not subject to seasonal fluctuations.
Overview of Protara Therapeutics, Inc.’s business
Protara Therapeutics is a clinical-stage biotechnology company focused on developing therapies for cancer and rare diseases. Their portfolio includes TARA-002, a cell-based therapy for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, a phospholipid substrate replacement therapy for patients on parenteral support. TARA-002 has received FDA designations, and IV Choline Chloride has Orphan Drug and Fast Track designations.
TARA’s Geographic footprint
Protara Therapeutics is headquartered in New York, with a primary focus on the U.S. market for the development and regulation of TARA-002 and IV Choline Chloride, although TARA-002 is based on a product approved in Japan and Taiwan.
TARA Corporate Image Assessment
Protara Therapeutics has generally maintained a positive reputation among financial analysts, with an average rating of "Moderate Buy" to "Buy". However, the company's reputation is sensitive to clinical trial data, as evidenced by a stock drop in February 2026 following updated Phase 2 trial data for TARA-002.
Ownership
Protara Therapeutics has a mixed ownership structure. Institutional investors hold a significant stake, between 71% and 78.74% of the shares. Individual investors hold around 11% of the stock, while insiders own approximately 2.79% to 3.37%. Hubert Birner is the largest individual shareholder.
